BioNTech (NASDAQ:BNTX) SE is a global biotechnology company headquartered in Mainz, Germany, focused on developing and commercializing novel immunotherapies for the treatment of cancer and infectious diseases. Established in 2008 by scientists Uğur Şahin, Özlem Türeci and Christoph Huber, the company has pioneered the use of messenger RNA (mRNA) technology to instruct the body’s own cells to produce disease-fighting proteins. BioNTech’s integrated development platform spans mRNA therapeutics, individualized cellular therapies, antibody-based approaches and innovative protein subunit technologies.
At the core of BioNTech’s business is its mRNA platform, which supports a broad pipeline of vaccine and therapeutic candidates. The company’s oncology portfolio includes individualized neoantigen therapies, CAR-T cell programs and bispecific antibodies aimed at mobilizing the immune system against solid tumors and hematological malignancies. In parallel, BioNTech has advanced mRNA-based vaccines for infectious diseases, most notably through its collaboration with Pfizer to develop the COVID-19 vaccine, which validated the speed and scalability of its manufacturing processes.
Since its initial public offering on the NASDAQ in 2019, BioNTech has expanded its global footprint and invested heavily in research and manufacturing capacity. The company operates production facilities in Europe and the United States, while partnering with regional distributors in Asia and Latin America to accelerate access to its products. BioNTech’s strategic alliances extend to pharmaceutical partners such as Pfizer, Fosun Pharma and Genentech, enabling co-development and commercialization of therapies across multiple indications.
Under the leadership of Chief Executive Officer Uğur Şahin and Chief Medical Officer Özlem Türeci, BioNTech maintains a science-driven culture with a focus on precision medicine. The executive management team and scientific advisory board bring deep expertise in immunology, oncology, vaccinology and regulatory affairs. Looking ahead, BioNTech aims to leverage its proprietary platforms to address unmet medical needs and deliver personalized treatments on a global scale.
